Carisma Therapeutics Inc.

CARMSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1485003

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue from Contract with Customer, Excluding Assessed Tax	$14.9M	$9.8M	—	—	—
Research and Development Expense	$74.1M	$56.6M	$29.2M	$24.7M	$14.1M
Operating Expenses	$103.7M	$66.0M	$32.3M	$108.5M	$34.5M
Operating Income (Loss)	-$88.7M	-$56.2M	-$21.1M	-$108.5M	-$34.5M
Nonoperating Income (Expense)	—	—	—	—	—
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	—	—	-$21.0M	-$107.5M	—
Income Tax Expense (Benefit)	—	—	$1.4M	$0.00	$0.00
Net Income (Loss) Attributable to Parent

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$89.6M	$72.2M	$240.7M	$122.8M	$114.4M
Assets, Current	$80.5M	$54.6M	$205.6M	$62.9M	$54.4M
Cash and Cash Equivalents, at Carrying Value	$77.6M	$24.2M	$52.4M	$48.1M	$50.4M
Accounts Receivable, after Allowance for Credit Loss, Current	—	—	$21.0M	$0.00	—
Liabilities	$63.0M	$107.0M	$69.0M	$132.1M	$141.1M
Liabilities, Current	$15.9M	$19.7M	$11.6M	$18.0M	$8.5M
Accounts Payable, Current	$3.9M	$1.7M	$2.9M	$3.1M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$81.2M	-$5.1M	-$30.8M	-$37.5M	-$22.8M
Net Cash Provided by (Used in) Investing Activities	$72.4M	-$32.6M	-$8.0K	-$136.0K	-$2.0K
Net Cash Provided by (Used in) Financing Activities	$62.2M	$33.3M	$38.1M	$35.4M	$58.6M
Payments to Acquire Property, Plant, and Equipment	$1.1M	$4.7M	—	$136.0K	$2.0K
Payments for Repurchase of Common Stock	—	—	—	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)